RLAY

Relay Therapeutics Inc. is a clinical-stage precision medicine company. The Company’s initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. Its Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company’s lead product candidates, such as RLY-2608. It is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including RLY-2608. RLY-2608 is an allosteric, pan-mutant and isoform-selective phosphoinostide 3 kinase alphas (PI3Kα), inhibitor in clinical development. It is the lead program in its efforts to discover and develop mutant selective inhibitors of PI3Kα.

Wall Street analysts forecast RLAY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RLAY is 15.25 USD with a low forecast of 14.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Relay Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

Relay Therapeutics Inc. EPS for the last quarter amounts to -0.43 USD, decreased -31.75 % YoY.

Relay Therapeutics Inc (RLAY) has 261 emplpoyees as of December 16 2025.

Today RLAY has the market capitalization of 1.47B USD.